

# Appendix 3Y

## Change of Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 30/9/2001.

|                       |                           |
|-----------------------|---------------------------|
| <b>Name of entity</b> | <b>4DS Memory Limited</b> |
| <b>ABN</b>            | 43 145 590 110            |

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

|                            |                           |
|----------------------------|---------------------------|
| <b>Name of Director</b>    | <b>Mr David McAuliffe</b> |
| <b>Date of last notice</b> | <b>7 May 2019</b>         |

### Part 1 - Change of director's relevant interests in securities

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

|   |  |
|---|--|
| <b>Direct or indirect interest</b>  | Direct and Indirect  |
| <b>Nature of indirect interest (including registered holder)</b><br><small>Note: Provide details of the circumstances giving rise to the relevant interest.</small> | Concept Biotech Pty Ltd (director related entity)<br>David Jerimiah McAuliffe <The Lazy D9M Investment Trust> (trustee and beneficiary)<br>Margaret Elizabeth Livingston (spouse)  |
| <b>Date of change</b>   | 29 November 2019   |
| <b>No. of securities held prior to change</b>   | <b>Direct</b><br><u>David McAuliffe</u><br>2,521,839 fully paid ordinary shares<br><b>Indirect</b><br><u>Concept Biotech Pty Ltd</u><br>2,498,812 fully paid ordinary shares<br><u>David Jerimiah McAuliffe&lt;D9M Investment Trust&gt;</u><br>8,056,743 fully paid ordinary shares<br><u>Margaret Elizabeth Livingston</u><br>7,000,000 unlisted options exercisable at \$0.052 each on or before 22 January 2024, with 1,250,000 subject to vesting conditions |
| <b>Class</b>  | Fully paid ordinary shares   |
| <b>Number acquired</b>  | Direct – 245,901   |
| <b>Number disposed</b>  | -  |

+ See chapter 19 for defined terms.

**Appendix 3Y**  
**Change of Director's Interest Notice**

|  |  |
|--|--|
| <b>Value/Consideration includes brokerage/gst</b><br><small>Note: If consideration is non-cash, provide details and estimated valuation</small>  | Non-cash consideration. Issue of shares in lieu of accrued salary at a deemed issue price of \$0.061 per share as approved by shareholders at the annual general meeting held on 29 November 2019.   |
| <b>No. of securities held after change</b>   | <b>Direct</b><br><u>David McAuliffe</u><br>2,767,740 fully paid ordinary shares<br><b>Indirect</b><br><u>Concept Biotech Pty Ltd</u><br>2,498,812 fully paid ordinary shares<br><u>David Jeremiah McAuliffe&lt;D9M Investment Trust&gt;</u><br>8,056,743 fully paid ordinary shares<br><u>Margaret Elizabeth Livingston</u><br>7,000,000 unlisted options exercisable at \$0.052 each on or before 22 January 2024, with 1,250,000 subject to vesting conditions |
| <b>Nature of change</b><br><small>Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back</small> | Issue of shares in lieu of accrued salary at a deemed issue price of \$0.061 per share as approved by shareholders at the annual general meeting held on 29 November 2019.   |

**Part 2 – Change of director's interests in contracts**

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

|   |      |
|---|------|
| <b>Detail of contract</b>   | N/A- |
| <b>Nature of interest</b>   | N/A  |
| <b>Name of registered holder (if issued securities)</b>   | N/A  |
| <b>Date of change</b>   | N/A  |
| <b>No. and class of securities to which interest related prior to change</b><br><small>Note: Details are only required for a contract in relation to which the interest has changed</small> | N/A  |
| <b>Interest acquired</b>  | N/A  |
| <b>Interest disposed</b>  | N/A  |
| <b>Value/Consideration</b><br><small>Note: If consideration is non-cash, provide details and an estimated valuation</small>   | N/A  |
| <b>Interest after change</b>  | N/A  |

**Part 3 – +Closed period**

|   |     |
|---|-----|
| Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required? | No  |
| If so, was prior written clearance provided to allow the trade to proceed during this period?   | N/A |
| If prior written clearance was provided, on what date was this provided?  | N/A |

+ See chapter 19 for defined terms.